Q1 FY26 Revenue Guidance

• Q1 FY26 sales revenue expected to exceed $5.5 million
• New quarterly revenue record, surpassing previous $5.0 million in Q4 FY25
• Continued strong growth during the September quarter-to-date

Biome Australia Limited (ASX: BIO), a microbiome health company, has announced that it expects its Q1 FY26 sales revenue to surpass $5.5 million. This result will establish a new quarterly revenue record for the company, exceeding the previous record of $5.0 million achieved in Q4 FY25. The company has reported that it has continued to experience strong growth during the September quarter-to-date. Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. The company aims to improve health outcomes and quality of life, and make its products accessible to all. Biome was incorporated in Australia in 2018 and distributes its products locally and abroad, in partnership with leading organisations in microbiome research and development.